Biotech entity
pharma is the sole category represented across all 1 tracked stories. Cladribine ODF is most often covered alongside BioNxt Solutions Inc., which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window.
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Cladribine ODF is most often covered alongside BioNxt Solutions Inc., which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window. At 6, the average consequence score sits below the same-window beat average of 6.3. We currently track 1 Biotech story that mention Cladribine ODF, all published on March 17, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cladribine ODF. Shared-story counts are live from our verified record — not editorial picks.
Bioequivalence Studies
Projected commencement of studies required for regional regulatory filings.
Strategic Agreement Signed
BioNxt announces a commercialization deal for Cladribine ODF in the Eurasian region.
Patent Grants Confirmed
Patents for the ODF formulation are officially granted in Europe and Eurasia.
BioNxt Solutions has entered a strategic partnership to commercialize its Cladribine Oral Dissolvable Film (ODF) across Eurasia, following successful patent approvals in both Europe and the Eurasian region. This move positions the company to capture market share in the Multiple Sclerosis (MS) treatment space with a novel, patient-friendly delivery mechanism.
Cladribine ODF is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
